Jun 13, 2024, 07:54
Connect to the ESMO Virtual Plenary to stay up to date with the latest in immunotherapy
ESMO shared on LinkedIn:
“What are the early safety and activity profiles of a first-in-class PD-1/IL-2 bispecific in patients with solid tumors?
Connect today to the ESMO Virtual Plenary with international experts in oncology to stay up to date with the latest in immunotherapy.”
Source: ESMO/LinkedIn